Keyphrases
Programmed Death-ligand 1 (PD-L1)
35%
Specific T Cells
32%
Vaccination
28%
Indoleamine 2,3-dioxygenase 1 (IDO1)
26%
T Cells
25%
Cancer Patients
21%
In Cancer
20%
Immune Response
19%
Epitope
19%
Tumor Antigen
19%
Myeloproliferative Neoplasms
18%
Tumor-infiltrating Lymphocytes
18%
Tumor Microenvironment
18%
Metastatic Melanoma
17%
T Cell Response
15%
CD8+ T Cells
15%
Tumor
15%
Cancer Cells
15%
Survivin
14%
Immune System
14%
Melanoma
14%
Immune Modulatory Vaccine
13%
Dendritic Cells
12%
Peptide Vaccine
12%
Peptide Vaccination
11%
Derived Peptide
11%
Clinical Response
11%
Autoreactive T Cells
11%
Therapeutic Vaccine
11%
Arginase-1 (Arg-1)
11%
Tumor Cells
11%
Immunogenicity
10%
HLA-A2
10%
Calreticulin
10%
Therapeutic Vaccination
9%
Immune Regulation
9%
Cancer Immunotherapy
9%
CD4+ T Cells
9%
Dendritic Cell Vaccine
9%
Adoptive Cell Therapy
9%
Cytotoxic T Cells
8%
Healthy Donors
8%
Regulatory T Cells
8%
Hematological Malignancies
8%
Chronic Myeloproliferative Neoplasms
8%
Malignant Melanoma
7%
Clinical Trials
7%
Immune Escape
7%
Cancer Immune Therapy
7%
Exon 9
7%
Immunology and Microbiology
T Cell
100%
Vaccination Policy
48%
Vaccine Efficacy
37%
Epitope
30%
Indoleamine 2,3-dioxygenase
23%
Immunotherapy
23%
Cytotoxic T-Cell
22%
Immune Response
22%
Cytotoxic T Cell
21%
Dendritic Cell
20%
Regulatory T Cell
19%
Cancer Cell
18%
Tumor Antigen
18%
Programmed Death-Ligand 1
16%
T-Helper Cell
16%
Tumor Cell
16%
Immune System
13%
Immunosuppressive Drug
13%
Cancer Vaccine
12%
Immunocompetent Cell
12%
Calreticulin
12%
Programmed Death 1 Ligand 1
11%
Cancer Immunotherapy
11%
CD8
11%
CD4
10%
Immunogenicity
9%
Tumor-Associated Macrophage
9%
Adoptive Immunity
8%
Peptide Vaccine
7%
Adaptive Immune System
7%
B Cell
7%
Human Leukocyte Antigen
6%
Immune Escape
6%
Myeloid
6%
Memory T Cell
6%
Tumor-Infiltrating Lymphocytes
5%
Cell Clone
5%
Tumor Necrosis Factor
5%
Mouse
5%
Immunoregulation
5%
Peripheral Blood Mononuclear Cell
5%
Cytokine
5%
Antigen Specificity
5%
Medicine and Dentistry
T Cell
33%
Neoplasm
26%
Malignant Neoplasm
18%
Cytotoxic T-Cell
17%
Nodular Melanoma
17%
Immunotherapy
16%
Myeloproliferative Neoplasm
14%
Tumor Infiltrating Lymphocyte
12%
Metastatic Melanoma
11%
Tumor Antigen
9%
Dendritic Cell
9%
T-Cell Response
8%
Immune Response
8%
Indoleamine 2,3 Dioxygenase
8%
Arginase 1
8%
Tumor Microenvironment
8%
Programmed Death-Ligand 1
6%
Cell Therapy
6%
Disease
6%
Peptide Vaccine
6%
T-Helper Cell
6%
Clinical Trial
5%
Programmed Death 1 Ligand 1
5%
